737 A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in patients with immunotherapy-sensitive locally advanced or metastatic solid tumors
Main Authors: | Brendan Curti, Igor Puzanov, Mateusz Opyrchal, Christopher J Nirschl, Mehmet A Bilen, Kristin Morris, Justin C Moser, Ildefonso Rodriguez Rivera, Saero Park, Marissa Bruno, Paul Windt, Kulandayan K Subramanian, Sameer S Chopra, Randi Isaacs |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
1074 PK/RO modeling of WTX-124, a tumor-activated IL-2 prodrug, highlights the potential for a substantially improved therapeutic index compared to other IL-2 molecules
by: Christopher J Nirschl, et al.
Published: (2023-11-01) -
1059 Spatial analysis of tumor infiltrating lymphocyte populations in syngeneic mouse tumor models after treatment with IL-12 (mWTX-330) and IL-2 (WTX-124) INDUKINETM molecules
by: Christopher J Nirschl, et al.
Published: (2023-11-01) -
1058 Optimal antitumor immunity triggered by WTX-124, a clinical stage conditionally activated INDUKINETM molecule that releases fully potent IL-2 in the tumor microenvironment
by: Christopher J Nirschl, et al.
Published: (2023-11-01) -
WTX beyond WNT signaling pathway
by: Zhang Qingling, et al.
Published: (2023-01-01) -
The <it>WTX/AMER1 </it>gene family: evolution, signature and function
by: Boutet Agnès, et al.
Published: (2010-09-01)